Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Praxis Precision Medicines (PRAX) Cash from Financing Activities: 2019-2024

Historic Cash from Financing Activities for Praxis Precision Medicines (PRAX) over the last 6 years, with Dec 2024 value amounting to $514.3 million.

  • Praxis Precision Medicines' Cash from Financing Activities rose 370.47% to $6.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $203.4 million, marking a year-over-year decrease of 49.73%. This contributed to the annual value of $514.3 million for FY2024, which is 459.83% up from last year.
  • Praxis Precision Medicines' Cash from Financing Activities amounted to $514.3 million in FY2024, which was up 459.83% from $91.9 million recorded in FY2023.
  • Praxis Precision Medicines' Cash from Financing Activities' 5-year high stood at $514.3 million during FY2024, with a 5-year trough of $10.5 million in FY2022.
  • In the last 3 years, Praxis Precision Medicines' Cash from Financing Activities had a median value of $91.9 million in 2023 and averaged $205.6 million.
  • Its Cash from Financing Activities has fluctuated over the past 5 years, first slumped by 90.27% in 2022, then skyrocketed by 777.89% in 2023.
  • Yearly analysis of 5 years shows Praxis Precision Medicines' Cash from Financing Activities stood at $304.4 million in 2020, then crashed by 64.66% to $107.6 million in 2021, then tumbled by 90.27% to $10.5 million in 2022, then skyrocketed by 777.89% to $91.9 million in 2023, then skyrocketed by 459.83% to $514.3 million in 2024.